LENSai™ Powered by HYFT® Technology Targets Universal Dengue Solution
AUSTIN, Texas – Artificial intelligence is making waves in the biotech world, and ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) is leading the charge. The company announced a breakthrough discovery: their proprietary LENSai™ platform, fueled by the patented HYFT® technology, has identified a highly conserved epitope across all four dengue virus serotypes. This finding is a significant leap forward in the quest for a universal dengue vaccine.
“This discovery marks a new era in AI-driven biology,” says Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. “By confirming that our sequence-derived HYFT patterns align with structural signatures across all dengue serotypes, we’re building a framework for universal vaccine design. The implications extend far beyond dengue, and research suggests this can be applied to address other infectious diseases and even certain cancers.”
Building on this initial success, IPA plans to expand its AI-driven vaccine design platform to combat other high-impact infectious diseases, including HIV, norovirus, and improved RSV vaccine development. Early-stage exploration into oncology for neoantigen vaccine development and tumor-specific epitope mapping is also underway.
Until now, finding a broadly effective dengue vaccine has been a monumental challenge. IPA’s discovery, achieved entirely via in silico methods, speaks to LENSai‘s capacity to harness big biological data to deliver actionable results. Traditional, often time-consuming approaches, have consistently failed to target a single point reliably across all four evolving serotypes.
The Dengue Dilemma: AI Poised to Crack a Decades-Long Problem
Why is a Universal Dengue Vaccine So Difficult?
Dengue presents a formidable foe. The four distinct, rapidly evolving serotypes mean that immunity to one doesn’t protect against others, and previous infections can actually worsen subsequent infections. Finding a viral component exposed and truly conserved across all four types has been a recurring challenge, further complicated by the virus’s fast mutation rate and the complex nature of immune responses.
A Breakthrough Confirmed: HYFT Patterns Match Across All Four Serotypes
Using its LENSai platform powered by the patented HYFT technology, IPA has pinpointed a specific viral signature, a strictly conserved epitope, across every dengue serotype. This target can be exploited to activate the immune system, potentially eliminating the virus.
This achievement is backed by a robust validation process:
- Sequence-based, patented HYFT patterns were independently verified to align with corresponding structural HYFTs across all four dengue serotypes.
- This was made possible through LENSai’s integration of over 20 million proprietary Structural HYFTs (S-HYFTs), enabling the platform to overlay three-dimensional conformations onto sequence-level fingerprints.
- LENSai can infer conformational and functional structures from sequence data alone, removing the need for laborious experimental methods.
This scientific triumph proves the patented HYFT technology’s unique ability to navigate the entire biological hierarchy—from DNA/RNA sequence to molecular structure to therapeutic applications. It signals that biology-first, AI-native designs can now provide valuable insights that previously were only attainable through years of wet-lab research.
The LENSai platform uses patented HYFT® patterns with deep learning, structural predictions, and literature-based knowledge graphs to rapidly identify and refine candidate epitopes, eliminating the need for experiments in the lab. The results: complete immunogen design and in silico immunogenicity screening. This drastically curtails development time and cuts costs in the early stages of vaccine development, unlocking fresh opportunities to address the most complex viral threats.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a technology-driven biotech company that uses modeling across multi-omics and extensive artificial intelligence via a series of proprietary and patented technologies. IPA possesses an all-encompassing, end-to-end suite of capabilities. They are known for solving complex industry challenges and supporting the development of therapeutic antibodies Its subsidiaries include Talem Therapeutics LLC, BioStrand BV, and ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V..
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Such forward-looking statements involve expressions like “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar wording, or those statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, adoption, and broader application of the LENSai™ and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery and vaccine development methods; the expansion of IPA’s discovery engine to additional infectious disease and oncology targets; and the Company’s ongoing ability to maintain scientific, regulatory, and commercial momentum.
Such statements are based on management’s projections and assumptions. Actual results may differ materially due to unknown and unpredicted factors, including scientific or technological developments, regulatory changes, market dynamics, and economic or business conditions.
These statements involve risks and uncertainties that could cause results to differ materially, including scientific or technological developments, changes in regulatory requirements, competitive dynamics, economic conditions, and others.
Readers are cautioned not to rely excessively on these forward-looking statements, and the company is under no obligation to revise these statements to reflect subsequent events or circumstances.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250605249893/en/
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/1809.html
